Trial reportPloS one2012
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.
Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00463060 (Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Journal of the National Cancer Institute · 2016Pooled it
- Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.Targeted oncology · 2014Trial
- Drug repurposing for cancer therapy.Signal transduction and targeted therapy · 2024Review
- Radiotherapy in the Management of Gastrointestinal Stromal Tumors: A Systematic Review.Cancers · 2022Review
- The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review.Translational andrology and urology · 2020Review
- Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.Journal of Cancer · 2020Review
- Signals from SABR-COMET time to move on to phase III studies.Annals of translational medicine · 2019Article
- Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine.The EPMA journal · 2019Review
- Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches".Annals of translational medicine · 2019Article
- Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.The oncologist · 2018Review
- Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2018Article
- Radiotherapy for Gastrointestinal Stromal Tumors.Chinese medical journal · 2018Review
- Article
- The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.Cancer growth and metastasis · 2018Review
- Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.Therapeutic advances in urology · 2017Review
- Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis.Oncology letters · 2016Article
- Treatment outcome of radiation therapy and concurrent targeted molecular therapy in spinal metastasis from renal cell carcinoma.Radiation oncology journal · 2016Article
- Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy.Frontiers in oncology · 2016Article
- Combining radiotherapy with sunitinib: lessons (to be) learned.Angiogenesis · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPreclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant metastases.
methodsTwenty five patients with oligometastases, defined as 1-5 sites of active disease on whole body imaging, were enrolled in a phase II trial from 2/08 to 9/10. The most common tumor types treated were head and neck, liver, lung, kidney and prostate cancers. Patients were treated with the recommended phase II dose of 37.5 mg daily sunitinib (days 1-28) and IGRT 50 Gy (days 8-12 and 15-19). Maintenance sunitinib was used in 33% of patients. Median follow up was 17.5 months (range, 0.7 to 37.4 months).
resultsThe 18-month local control, distant control, progression-free survival (PFS) and overall survival (OS) were 75%, 52%, 56% and 71%, respectively. At last follow-up, 11 (44%) patients were alive without evidence of disease, 7 (28%) were alive with distant metastases, 3 (12%) were dead from distant metastases, 3 (12%) were dead from comorbid illness, and 1 (4%) was dead from treatment-related toxicities. The incidence of acute grade ≥ 3 toxicities was 28%, most commonly myelosuppression, bleeding and abnormal liver function tests.
conclusionsConcurrent sunitinib and IGRT achieves major clinical responses in a subset of patients with oligometastases.
trial registrationClinicalTrials.gov NCT00463060.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.